A Prospective Randomized Trial Comparing Partial Hepatectomy and TACE Plus PEI for Small Hepatocellular Carcinoma

randomly put in group standard:

• via clinical diagnosis and confirm it is primary liver cancer, and not accept any anticancer treatment.
• age: 18-70 years.
• early hepatocyte cancer，which is single focus of infection diameter ≤ 3 cm.
• estimate tumor can gain treatment of curing operation or TACE plus PEI.
• better liver function (Child-Pugh，class A or B).

Case loads: 160 residents with small hepatocellular carcinoma in China

Therapeutic regimen: under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.

Research end-point:

• ensemble life span.To compare 1、2 and 3 year overall survival rate in hepatectomy and TACE plus PEI for small hepatocellular carcinoma
• intraliver recurrence rate; distant metastasis rate; non-tumor life span; band tumor life span

Telephone call at any time

Inclusion criteria

• via clinical diagnosis and confirm it is primary liver cancer, and not accept any anticancer treatment.
• age:18-70years
• early hepatocyte cancer，which is single focus of infection diameter ≤3cm.
• estimate tumor can gain treatment of curing operation or micro-create treatment combineation
• better liver function (Child-Pugh，class A or B)

Exclusion criteria

• reject to attend；
• impossible to come to our hospital for physical examination regularly.
• cancer epitome、seed focus、lymph node or distant metastasis
• Blood clotting function hindrance;
• serious heart、lung、kidney disease.